Study Funding
Neurologic Disorders, Stroke
NEUROLOGIC DISORDERS, STROKE
The IMS III trial was funded by the NIH and National Institute of Neurologic Disorders and Stroke, grant numbers: University of Cincinnati (U01NS052220) and Medical University of South Carolina (U01NS054630 and U01NS077304). Genentech supplied the study drug used for intra-arterial tissue-type plasminogen activator treatment in the endovascular group. EKOS, Concentric Medical, and Cordis supplied study catheters during protocol versions 1–3. In the United States, IMS III trial investigator meeting support was provided in part by Genentech, EKOS, and Concentric Medical. In Europe, IMS III trial investigator meeting support was provided in part by Boehringer Ingelheim.